Non-Polio enterovirus infections pathophysiology: Difference between revisions

Jump to navigation Jump to search
Line 4: Line 4:


==Overview==
==Overview==
[[Enteroviral]] [[diseases]] are more likely to be severe in the [[immunocompromised]], including [[patients]] with [[diabetes]], [[HIV]], [[neoplasm]], or [[post-transplant]] status.The [[cellular]] uptake of [[enteorviruses]] is mediated by [[receptor]] [[molecules]] such as, [[intracellular]] [[adhesion]] [[molecule]]-1 ([[ICAM-1)]], low-density [[lipoprotein]] [[receptor]] ([[LDL-R]]), and [[non-protein]] factors such as [[heparan sulfate]] and [[sialic acid]]. [[Incubation]] [[periods]] range from 12 hours to 5 days, with [[experimental]] volunteers reporting [[symptoms]] several hours after aritficial [[inoculation]].
[[Enteroviral]] [[diseases]] are more likely to be severe in the [[immunocompromised]], including [[patients]] with [[diabetes]], [[HIV]], [[neoplasms]], or [[post-transplant]] status.The [[cellular]] uptake of [[enteorviruses]] is mediated by [[receptor]] [[molecules]] such as, [[intracellular]] [[adhesion]] [[molecule]]-1 ([[ICAM-1)]], low-density [[lipoprotein]] [[receptor]] ([[LDL-R]]), and [[non-protein]] factors such as [[heparan sulfate]] and [[sialic acid]]. [[Incubation]] [[periods]] range from 12 hours to 5 days, with [[experimental]] volunteers reporting [[symptoms]] several hours after aritficial [[inoculation]].


==Pathophysiology==
==Pathophysiology==

Revision as of 19:01, 4 February 2023

Non-Polio enterovirus infections Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Non-Polio enterovirus infections from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Non-Polio enterovirus infections pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Non-Polio enterovirus infections pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Non-Polio enterovirus infections pathophysiology

CDC on Non-Polio enterovirus infections pathophysiology

Non-Polio enterovirus infections pathophysiology in the news

Blogs on Non-Polio enterovirus infections pathophysiology

Directions to Hospitals Treating Non-Polio enterovirus infections

Risk calculators and risk factors for Non-Polio enterovirus infections pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: {Sujaya}}

Overview

Enteroviral diseases are more likely to be severe in the immunocompromised, including patients with diabetes, HIV, neoplasms, or post-transplant status.The cellular uptake of enteorviruses is mediated by receptor molecules such as, intracellular adhesion molecule-1 (ICAM-1), low-density lipoprotein receptor (LDL-R), and non-protein factors such as heparan sulfate and sialic acid. Incubation periods range from 12 hours to 5 days, with experimental volunteers reporting symptoms several hours after aritficial inoculation.

Pathophysiology

Non-polio non-rhinovirus enteroviruses

Rhinoviruses

References


Template:WikiDoc Sources